The American College of Surgeons Oncology Group (ACOSOG) was recently established to define the role of surgical therapies in patients with malignant solid tumors. The ACOSOG incorporates general and specialty surgical oncologists, and non-surgical oncologists, in academic medical centers and community practice throughout the United States of America and in foreign countries. This surgical group is important to the oncological community because of the primary role of surgery in the treatment of the cancer patient. Also the interrelationship of the ACOSOG with the American College of Surgeons (ACOS) provides a unique opportunity to utilize evidenced based medicine to educate large number of surgeons in the standard of care for the cancer patient. ACOSOG trials will evaluate several areas of surgical and basic oncology. The most important are: a) new and existing operative procedures; b) new technology and devices, c) diagnostic molecular markers and therapeutic biologic agents, d) radiographic imaging procedures, and e) interventional therapy in patients demonstrated to have a genetic predisposition for cancer. ACOSOG will also perform multimodality therapeutic trials in patients with certain solid tumors that are less accessible to other cooperative groups because they are uncommon and are treated primarily by surgical resection. ACOSOG will participate in Intergroup studies when the Group's resources and access to surgical patients can substantially enhance accrual to those trials. ACOSOG benefits from its strong relationship with the American College of Surgeons (ACS), the largest organization of surgeons in the world with broad geographic membership including general and specialty surgeons in both academic and private practice. This broad membership also positions ACOSOG to offer clinical trials to women, minorities and underserved populations. In addition, for purposes of institutional auditing and physician education, ACOSOG will interact closely with the Commission on Cancer (COC) of the ACS which has a large staff serving the Cancer Programs of almost 1500 approved hospitals across North America. ACOSOG is committed to lowering cancer incidence and mortality through innovative clinical trials that allow broad physician and patient participation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Schools of Medicine
United States
Zip Code
Le-Petross, Huong T; McCall, Linda M; Hunt, Kelly K et al. (2018) Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). AJR Am J Roentgenol 210:669-676
Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198
Brown, Paul D; Ballman, Karla V; Cerhan, Jane H et al. (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CECĀ·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049-1060
Churilla, Thomas M; Ballman, Karla V; Brown, Paul D et al. (2017) Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. Int J Radiat Oncol Biol Phys 99:1173-1178
Ellis, Matthew J; Suman, Vera J; Hoog, Jeremy et al. (2017) Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 35:1061-1069
Miller, Christopher A; Gindin, Yevgeniy; Lu, Charles et al. (2016) Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 7:12498
Brown, Paul D; Jaeckle, Kurt; Ballman, Karla V et al. (2016) Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA 316:401-409
Haffty, Bruce G; McCall, Linda M; Ballman, Karla V et al. (2016) Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). Int J Radiat Oncol Biol Phys 94:493-502
Kent, Michael S; Mandrekar, Sumithra J; Landreneau, Rodney et al. (2016) Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). Ann Thorac Surg 102:230-8
Boughey, Judy C; Ballman, Karla V; Le-Petross, Huong T et al. (2016) Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) Ann Surg 263:802-7

Showing the most recent 10 out of 68 publications